{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:17:47Z","timestamp":1780352267052,"version":"3.54.1"},"publisher-location":"Cham","reference-count":106,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319403182","type":"print"},{"value":"9783319403205","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-3-319-40320-5_12","type":"book-chapter","created":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T12:01:09Z","timestamp":1475323269000},"page":"207-225","source":"Crossref","is-referenced-by-count":23,"title":["Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma"],"prefix":"10.1007","author":[{"given":"Susan J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Borrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,2]]},"reference":[{"key":"12_CR1","doi-asserted-by":"crossref","first-page":"e106914","DOI":"10.1371\/journal.pone.0106914","volume":"9","author":"M Alifano","year":"2014","unstructured":"Alifano M et al (2014) Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS ONE 9:e106914\u201311","journal-title":"PLoS ONE"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-14-0493","volume":"20","author":"G Song","year":"2014","unstructured":"Song G et al (2014) Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clin Cancer Res 20:6083\u20136095","journal-title":"Clin Cancer Res"},{"key":"12_CR3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/imm.12380","volume":"143","author":"V Kumar","year":"2014","unstructured":"Kumar V, Gabrilovich DI (2014) Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology 143:512\u2013519","journal-title":"Immunology"},{"key":"12_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/157496","volume":"2012","author":"S Manier","year":"2012","unstructured":"Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM (2012) Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol 2012:1\u20135","journal-title":"J Biomed Biotechnol"},{"key":"12_CR5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/stem.787","volume":"30","author":"S Xu","year":"2012","unstructured":"Xu S et al (2012) Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells 30:266\u2013279","journal-title":"Stem Cells"},{"key":"12_CR6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","volume":"114","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M et al (2009) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:371\u2013379","journal-title":"Blood"},{"key":"12_CR7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1084\/jem.20062387","volume":"204","author":"R Spisek","year":"2007","unstructured":"Spisek R et al (2007) Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 204:831\u2013840","journal-title":"J Exp Med"},{"key":"12_CR8","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/bcj.2013.34","volume":"3","author":"C Bryant","year":"2013","unstructured":"Bryant C et al (2013) Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance. Blood Cancer J 3:e148","journal-title":"Blood Cancer J"},{"key":"12_CR9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/147323001204000217","volume":"40","author":"CJ Shen","year":"2012","unstructured":"Shen CJ, Yuan ZH, Liu YX, Hu GY (2012) Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma. J Int Med Res 40:556\u2013564","journal-title":"J Int Med Res"},{"key":"12_CR10","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.3109\/10428194.2014.904511","volume":"55","author":"J Favaloro","year":"2014","unstructured":"Favaloro J et al (2014) Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk Lymphoma 55:2893\u20132900","journal-title":"Leuk Lymphoma"},{"key":"12_CR11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ni1488","volume":"8","author":"L Zhou","year":"2007","unstructured":"Zhou L et al (2007) IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8:967\u2013974","journal-title":"Nat Immunol"},{"key":"12_CR12","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood.V74.4.1266.1266","volume":"74","author":"A Lichtenstein","year":"1989","unstructured":"Lichtenstein A, Berenson J, Norman D, Chang M-P, Charlie A (1989) Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74:1266\u20131273","journal-title":"Blood"},{"key":"12_CR13","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","volume":"116","author":"K Noonan","year":"2010","unstructured":"Noonan K et al (2010) A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 116:3554\u20133563","journal-title":"Blood"},{"key":"12_CR14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1084\/jem.190.7.995","volume":"190","author":"C Asseman","year":"1999","unstructured":"Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F (1999) An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190:995\u20131004","journal-title":"J Exp Med"},{"key":"12_CR15","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.4049\/jimmunol.168.3.1080","volume":"168","author":"CI Kingsley","year":"2002","unstructured":"Kingsley CI, Karim M, Bushell AR, Wood KJ (2002) CD25+CD4+\u00a0regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 168:1080\u20131086","journal-title":"J Immunol"},{"key":"12_CR16","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.20051511","volume":"202","author":"F Ghiringhelli","year":"2005","unstructured":"Ghiringhelli F (2005) CD4+CD25+\u00a0regulatory T cells inhibit natural killer cell functions in a transforming growth factor-dependent manner. J Exp Med 202:1075\u20131085","journal-title":"J Exp Med"},{"key":"12_CR17","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1158\/1078-0432.CCR-07-0472","volume":"13","author":"L Strauss","year":"2007","unstructured":"Strauss L et al (2007) A unique subset of CD4+CD25highFoxp3+\u00a0T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13:4345\u20134354","journal-title":"Clin Cancer Res"},{"key":"12_CR18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1084\/jem.20040685","volume":"201","author":"L Fahlen","year":"2005","unstructured":"Fahlen L (2005) T cells that cannot respond to TGF- escape control by CD4+CD25+\u00a0regulatory T cells. J Exp Med 201:737\u2013746","journal-title":"J Exp Med"},{"key":"12_CR19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/359693a0","volume":"359","author":"MM Shull","year":"1992","unstructured":"Shull MM et al (1992) Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:693\u2013699","journal-title":"Nature"},{"key":"12_CR20","doi-asserted-by":"crossref","first-page":"e47077","DOI":"10.1371\/journal.pone.0047077","volume":"7","author":"KR Muthu Raja","year":"2012","unstructured":"Muthu Raja KR et al (2012) Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS ONE 7:e47077\u201311","journal-title":"PLoS ONE"},{"key":"12_CR21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bjc.2011.575","volume":"106","author":"K Giannopoulos","year":"2012","unstructured":"Giannopoulos K, Kaminska W, Hus I, Dmoszynska A (2012) The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer 106:546\u2013552","journal-title":"Br J Cancer"},{"key":"12_CR22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","volume":"107","author":"RH Prabhala","year":"2006","unstructured":"Prabhala RH (2006) Dysfunctional T regulatory cells in multiple myeloma. Blood 107:301\u2013304","journal-title":"Blood"},{"key":"12_CR23","doi-asserted-by":"crossref","first-page":"e49446","DOI":"10.1371\/journal.pone.0049446","volume":"7","author":"KR Muthu Raja","year":"2012","unstructured":"Muthu Raja KR et al (2012) Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS ONE 7:e49446\u201310","journal-title":"PLoS ONE"},{"key":"12_CR24","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/eji.201040485","volume":"40","author":"V Ablamunits","year":"2010","unstructured":"Ablamunits V, Bisikirska B, Herold KC (2010) Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol 40:2891\u20132901","journal-title":"Eur J Immunol"},{"key":"12_CR25","doi-asserted-by":"crossref","first-page":"e35981","DOI":"10.1371\/journal.pone.0035981","volume":"7","author":"S Feyler","year":"2012","unstructured":"Feyler S et al (2012) Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS ONE 7:e35981\u201310","journal-title":"PLoS ONE"},{"key":"12_CR26","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.bbmt.2014.03.007","volume":"20","author":"J Rueff","year":"2014","unstructured":"Rueff J, Medinger M, Heim D, Passweg J, Stern M (2014) Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biol Blood Marrow Transplant 20:896\u2013899","journal-title":"Biol Blood Marrow Transplant"},{"key":"12_CR27","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","volume":"116","author":"DM Benson","year":"2010","unstructured":"Benson DM et al (2010) The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116:2286\u20132294","journal-title":"Blood"},{"key":"12_CR28","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/trf.12517","volume":"54","author":"L Talebian","year":"2014","unstructured":"Talebian L et al (2014) The natural killer-activating receptor, NKG2D, on CD3+CD8+\u00a0T cells plays a critical role in identifying and killing autologous myeloma cells. Transfusion 54:1515\u20131521","journal-title":"Transfusion"},{"key":"12_CR29","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0711293105","volume":"105","author":"M Jinushi","year":"2008","unstructured":"Jinushi M et al (2008) MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci 105:1285\u20131290","journal-title":"Proc Natl Acad Sci"},{"key":"12_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5604\/17322693.1028763","volume":"67","author":"M Pasiarski","year":"2013","unstructured":"Pasiarski M, Grywalska E, Kosmaczewska A, Gozdz S, Rolinski J (2013) The frequency of myeloid and lymphoid dendritic cells in multiple myeloma patients is inversely correlated with disease progression. Potepy Hig Med Dosw 67:1\u20137","journal-title":"Potepy Hig Med Dosw"},{"key":"12_CR31","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V100.1.230","volume":"100","author":"M Ratta","year":"2002","unstructured":"Ratta M et al (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100:230\u2013237","journal-title":"Blood"},{"key":"12_CR32","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","volume":"190","author":"IR Ramachandran","year":"2013","unstructured":"Ramachandran IR et al (2013) Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol 190:3815\u20133823","journal-title":"J Immunol"},{"key":"12_CR33","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","volume":"121","author":"GT G\u00f6rg\u00fcn","year":"2013","unstructured":"G\u00f6rg\u00fcn GT et al (2013) Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 121:2975\u20132987","journal-title":"Blood"},{"key":"12_CR34","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1084\/jem.20061104","volume":"203","author":"P Serafini","year":"2006","unstructured":"Serafini P et al (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203:2691\u20132702","journal-title":"J Exp Med"},{"key":"12_CR35","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/2326-6066.CIR-13-0213","volume":"2","author":"KA Noonan","year":"2014","unstructured":"Noonan KA, Ghosh N, Rudraraju L, Bui M, Borrello I (2014) Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunol Res 2:725\u2013731","journal-title":"Cancer Immunol Res"},{"key":"12_CR36","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood.V95.10.3011","volume":"95","author":"I Borrello","year":"2000","unstructured":"Borrello I et al (2000) Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)\u2013producing tumor vaccines. Blood 95:3011\u20133019","journal-title":"Blood"},{"key":"12_CR37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/asheducation-2000.1.69","volume":"2000","author":"NC Gorin","year":"2000","unstructured":"Gorin NC (2000) New developments in the therapy of acute myelocytic leukemia. Hematology 2000:69\u201389","journal-title":"Hematology"},{"key":"12_CR38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/bmt.2012.167","volume":"48","author":"S Gerull","year":"2013","unstructured":"Gerull S et al (2013) Allo-SCT for multiple myeloma in the era of novel agents: a retrospective study on behalf of Swiss Blood SCT. Bone Marrow Transplant 48:408\u2013413","journal-title":"Bone Marrow Transplant"},{"key":"12_CR39","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","volume":"88","author":"BB Bjorkstrand","year":"1996","unstructured":"Bjorkstrand BB et al (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88:4711\u20134718","journal-title":"Blood"},{"key":"12_CR40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/sj.bmt.1701975","volume":"24","author":"G Gahrton","year":"1999","unstructured":"Gahrton G et al (1999) Syngeneic transplantation in multiple myeloma\u2014a case-matched comparison with autologous and allogeneic transplantation. Bone Marrow Transplant 24:741\u2013745","journal-title":"Bone Marrow Transplant"},{"key":"12_CR41","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie B (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321. J Clin Oncol 24:929\u2013936","journal-title":"J Clin Oncol"},{"key":"12_CR42","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","volume":"124","author":"CG Kanakry","year":"2014","unstructured":"Kanakry CG et al (2014) Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 124:3817\u20133827","journal-title":"Blood"},{"key":"12_CR43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.immuni.2005.01.008","volume":"22","author":"IB Mazo","year":"2005","unstructured":"Mazo IB et al (2005) Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity 22:259\u2013270","journal-title":"Immunity"},{"key":"12_CR44","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.it.2005.04.011","volume":"26","author":"F Rosa Di","year":"2005","unstructured":"Di Rosa F, Pabst R (2005) The bone marrow: a nest for migratory memory T cells. Trends Immunol 26:360\u2013366","journal-title":"Trends Immunol"},{"key":"12_CR45","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/0008-5472.CAN-04-3337","volume":"65","author":"K Noonan","year":"2005","unstructured":"Noonan K et al (2005) Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 65:2026\u20132034","journal-title":"Cancer Res"},{"key":"12_CR46","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","volume":"28","author":"J Chu","year":"2014","unstructured":"Chu J et al (2014) CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28:917\u2013927","journal-title":"Leukemia"},{"key":"12_CR47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","volume":"8","author":"H Jiang","year":"2014","unstructured":"Jiang H et al (2014) Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol 8:297\u2013310","journal-title":"Mol Oncol"},{"key":"12_CR48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbmt.2012.08.018","volume":"19","author":"KR Meehan","year":"2013","unstructured":"Meehan KR et al (2013) Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+\u00a0T cells after autologous transplantation for myeloma. Biol Blood Marrow Transplant 19:129\u2013137","journal-title":"Biol Blood Marrow Transplant"},{"key":"12_CR49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2141.2007.06832.x","volume":"139","author":"A Curti","year":"2007","unstructured":"Curti A et al (2007) Phase I\/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol 139:415\u2013424","journal-title":"Br J Haematol"},{"key":"12_CR50","doi-asserted-by":"crossref","unstructured":"Reichardt VL et al (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma\u2014a feasibility study. Blood 93:2411\u20132419","DOI":"10.1182\/blood.V93.7.2411"},{"key":"12_CR51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<215::AID-IJC12>3.0.CO;2-Q","volume":"83","author":"SH Lim","year":"1999","unstructured":"Lim SH, Bailey-Wood R (1999) Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 83:215\u2013222","journal-title":"Int J Cancer"},{"key":"12_CR52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1365-2141.2002.03411.x","volume":"117","author":"Q Yi","year":"2002","unstructured":"Yi Q, Desikan R, Barlogie B, Munshi N (2002) Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 117:297\u2013305","journal-title":"Br J Haematol"},{"key":"12_CR53","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/CJI.0b013e3181facf48","volume":"34","author":"C Rollig","year":"2011","unstructured":"Rollig C et al (2011) Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J Immunother 34:100\u2013106","journal-title":"J Immunother"},{"key":"12_CR54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2249.2012.04642.x","volume":"170","author":"S Hong","year":"2012","unstructured":"Hong S et al (2012) Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol 170:167\u2013177","journal-title":"Clin Exp Immunol"},{"key":"12_CR55","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","volume":"19","author":"J Rosenblatt","year":"2013","unstructured":"Rosenblatt J et al (2013) Vaccination with dendritic cell\/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 19:3640\u20133648","journal-title":"Clin Cancer Res"},{"key":"12_CR56","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2007-07-099366","volume":"111","author":"M Schmitt","year":"2007","unstructured":"Schmitt M et al (2007) RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111:1357\u20131365","journal-title":"Blood"},{"key":"12_CR57","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2009.014704","volume":"95","author":"J Greiner","year":"2010","unstructured":"Greiner J et al (2010) High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 95:1191\u20131197","journal-title":"Haematologica"},{"key":"12_CR58","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1158\/1078-0432.CCR-04-0825","volume":"10","author":"T Azuma","year":"2004","unstructured":"Azuma T (2004) Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 10:7402\u20137412","journal-title":"Clin Cancer Res"},{"key":"12_CR59","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF02983998","volume":"86","author":"A Tsuboi","year":"2007","unstructured":"Tsuboi A et al (2007) Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol 86:414\u2013417","journal-title":"Int J Hematol"},{"key":"12_CR60","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.V124.21.2137.2137","volume":"124","author":"K Noonan","year":"2014","unstructured":"Noonan K et al (2014) Lenalidomide immunomodulation with an allogeneic myeloma GVAX in a near complete remission induces durable clinical remissions. Blood 124:2137","journal-title":"Blood"},{"key":"12_CR61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.1991.tb07975.x","volume":"77","author":"JFS Miguel","year":"1990","unstructured":"Miguel JFS et al (1990) Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Br J Haematol 77:185\u2013190","journal-title":"Br J Haematol"},{"key":"12_CR62","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","volume":"103","author":"W Matsui","year":"2004","unstructured":"Matsui W et al (2004) Characterization of clonogenic multiple myeloma cells. Blood 103:2332\u20132336","journal-title":"Blood"},{"key":"12_CR63","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00002371-200201000-00008","volume":"25","author":"SP Treon","year":"2002","unstructured":"Treon SP et al (2002) CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 25:72\u201381","journal-title":"J Immunother"},{"key":"12_CR64","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/10428190600564803","volume":"47","author":"N Zojer","year":"2006","unstructured":"Zojer N, Kirchbacher K, Vesely M, H\u00fcbl W, Ludwig H (2006) Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma 47:1103\u20131109","journal-title":"Leuk Lymphoma"},{"key":"12_CR65","doi-asserted-by":"publisher","unstructured":"Moreau P et al (2007) Rituximab in CD20 positive multiple myeloma. Leukemia 1\u20132. doi: 10.1038\/sj.leu.2404558","DOI":"10.1038\/sj.leu.2404558"},{"key":"12_CR66","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1182\/blood-2006-01-013003","volume":"108","author":"S Deaglio","year":"2006","unstructured":"Deaglio S (2006) In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 108:1135\u20131144","journal-title":"Blood"},{"key":"12_CR67","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","volume":"1","author":"MS Veer van der","year":"2011","unstructured":"van der Veer MS et al (2011) The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J 1:e41\u2013e43","journal-title":"Blood Cancer J"},{"key":"12_CR68","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M Weers de","year":"2011","unstructured":"de Weers M et al (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186:1840\u20131848","journal-title":"J Immunol"},{"key":"12_CR69","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1182\/blood.V120.21.2974.2974","volume":"120","author":"JHM Jansen","year":"2012","unstructured":"Jansen JHM et al (2012) Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. Blood 120:2974","journal-title":"Blood"},{"key":"12_CR70","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/blood.V120.21.4054.4054","volume":"120","author":"MB Overdijk","year":"2012","unstructured":"Overdijk MB et al (2012) Phagocytosis is a mechanism of action for daratumumab. Blood 120:4054","journal-title":"Blood"},{"key":"12_CR71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood-2012-04-416594","volume":"120","author":"T Plesner","year":"2012","unstructured":"Plesner T et al (2012) Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma\u2014data from a dose-escalation phase I\/II study. Blood 120:73","journal-title":"Blood"},{"key":"12_CR72","first-page":"1986","volume":"122","author":"T Plesner","year":"2013","unstructured":"Plesner T et al (2013) Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. Blood 122:1986","journal-title":"Blood"},{"key":"12_CR73","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","volume":"20","author":"J Deckert","year":"2014","unstructured":"Deckert J et al (2014) SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+\u00a0hematologic malignancies. Clin Cancer Res 20:4574\u20134583","journal-title":"Clin Cancer Res"},{"key":"12_CR74","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/blood.V81.10.2658.2658","volume":"81","author":"H Harada","year":"1993","unstructured":"Harada H et al (1993) Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81:2658\u20132663","journal-title":"Blood"},{"key":"12_CR75","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1182\/blood.V116.21.1962.1962","volume":"116","author":"A Chanan-Khan","year":"2010","unstructured":"Chanan-Khan A et al (2010) Efficacy analysis from phase I study of Lorvotuzumab mertansine(IMGN901), used as monotherapy, in patients with heavily pre-treated CD56-positive multiple myeloma\u2014a preliminary efficacy analysis. Blood 116:1962","journal-title":"Blood"},{"key":"12_CR76","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1182\/blood.V120.21.4048.4048","volume":"120","author":"JG Berdeja","year":"2012","unstructured":"Berdeja JG et al (2012) Phase i study of Lorvotuzumab mertansine (LM, IMGN901) in combination with Lenalidomide (Len) and Dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed\/refractory multiple myeloma (MM). Blood 120:4048","journal-title":"Blood"},{"key":"12_CR77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-5890(02)00094-9","volume":"39","author":"PR Kumaresan","year":"2002","unstructured":"Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA (2002) CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol 39:1\u20138","journal-title":"Mol Immunol"},{"key":"12_CR78","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","volume":"120","author":"JA Zonder","year":"2012","unstructured":"Zonder JA et al (2012) A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120:552\u2013559","journal-title":"Blood"},{"key":"12_CR79","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","volume":"30","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ et al (2012) Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma. J Clin Oncol 30:1960\u20131965","journal-title":"J Clin Oncol"},{"key":"12_CR80","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","volume":"30","author":"S Lonial","year":"2012","unstructured":"Lonial S et al (2012) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 30:1953\u20131959","journal-title":"J Clin Oncol"},{"key":"12_CR81","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2009.008003","volume":"95","author":"M Hussein","year":"2010","unstructured":"Hussein M et al (2010) A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 95:845\u2013848","journal-title":"Haematologica"},{"key":"12_CR82","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2012.09251.x","volume":"159","author":"W Bensinger","year":"2012","unstructured":"Bensinger W et al (2012) A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol 159:58\u201366","journal-title":"Br J Haematol"},{"key":"12_CR83","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","volume":"19","author":"R Kurzrock","year":"2013","unstructured":"Kurzrock R et al (2013) A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 19:3659\u20133670","journal-title":"Clin Cancer Res"},{"key":"12_CR84","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","volume":"161","author":"PM Voorhees","year":"2013","unstructured":"Voorhees PM et al (2013) A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 161:357\u2013366","journal-title":"Br J Haematol"},{"key":"12_CR85","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","volume":"123","author":"J San-Miguel","year":"2014","unstructured":"San-Miguel J et al (2014) Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123:4136\u20134142","journal-title":"Blood"},{"key":"12_CR86","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/jid.2011.30","volume":"131","author":"M Chapon","year":"2011","unstructured":"Chapon M et al (2011) Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes. Journal of Investigative Dermatology 131:1300\u20131307","journal-title":"Journal of Investigative Dermatology"},{"key":"12_CR87","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24:207\u2013212","journal-title":"Curr Opin Immunol"},{"key":"12_CR88","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/eji.201243275","volume":"43","author":"S Yao","year":"2013","unstructured":"Yao S, Chen L (2013) Adaptive resistance: a tumor strategy to evade immune attack. Eur J Immunol 43:576\u2013579","journal-title":"Eur J Immunol"},{"key":"12_CR89","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci 99:12293\u201312297","journal-title":"Proc Natl Acad Sci"},{"key":"12_CR90","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving Nivolumab. J Clin Oncol 32:1020\u20131030","journal-title":"J Clin Oncol"},{"key":"12_CR91","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR et al (2012) Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455\u20132465","journal-title":"N Engl J Med"},{"key":"12_CR92","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM et al (2015) PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372:311\u2013319","journal-title":"N Engl J Med"},{"key":"12_CR93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/107327481402100112","volume":"21","author":"BC Creelan","year":"2014","unstructured":"Creelan BC (2014) Update on immune checkpoint inhibitors in lung cancer. Cancer Control 21:1\u201310","journal-title":"Cancer Control"},{"key":"12_CR94","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood.V124.21.291.291","volume":"124","author":"AM Lesokhin","year":"2014","unstructured":"Lesokhin AM et al (2014) Preliminary results of a phase I study of Nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 124:291\u2013291","journal-title":"Blood"},{"key":"12_CR95","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.4049\/jimmunol.1202005","volume":"190","author":"TJ Kearl","year":"2013","unstructured":"Kearl TJ, Jing W, Gershan JA, Johnson BD (2013) Programmed death receptor-1\/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol 190:5620\u20135628","journal-title":"J Immunol"},{"key":"12_CR96","doi-asserted-by":"crossref","unstructured":"Schneider H et al (2006) Reversal of the TCR stop Signal by CTLA-4. Sci 313(5795):1972\u20135","DOI":"10.1126\/science.1131078"},{"key":"12_CR97","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4049\/jimmunol.182.1.274","volume":"182","author":"EM Schmidt","year":"2008","unstructured":"Schmidt EM et al (2008) CTLA-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J Immunol 182:274\u2013282","journal-title":"J Immunol"},{"key":"12_CR98","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1084\/jem.20081811","volume":"206","author":"RH Friedline","year":"2009","unstructured":"Friedline RH et al (2009) CD4+\u00a0regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 206:421\u2013434","journal-title":"J Exp Med"},{"key":"12_CR99","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.V118.21.1829.1829","volume":"118","author":"WMT Braga","year":"2011","unstructured":"Braga WMT, Vettore AL, Carvalho AC, Atanackovic D, Colleoni GWB (2011) Overexpression of CTLA-4 in the bone marrow of patients with multiple myeloma as a sign of local accumulation of immunosuppressive Tregs\u2014perspectives for novel treatment strategies. Blood 118:1829","journal-title":"Blood"},{"key":"12_CR100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"12_CR101","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00262-014-1571-6","volume":"63","author":"B Keersmaecker De","year":"2014","unstructured":"De Keersmaecker B et al (2014) Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation. Cancer Immunol Immunother 63:1023\u20131036","journal-title":"Cancer Immunol Immunother"},{"key":"12_CR102","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","volume":"18","author":"K Noonan","year":"2012","unstructured":"Noonan K et al (2012) Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res 18:1426\u20131434","journal-title":"Clin Cancer Res"},{"key":"12_CR103","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2009-02-200543","volume":"114","author":"Y Xu","year":"2009","unstructured":"Xu Y et al (2009) Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 114:338\u2013345","journal-title":"Blood"},{"key":"12_CR104","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/imm.12087","volume":"139","author":"JY Henry","year":"2013","unstructured":"Henry JY et al (2013) Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs \u00aeimmunomodulatory compounds lenalidomide and pomalidomide. Immunology 139:377\u2013385","journal-title":"Immunology"},{"key":"12_CR105","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3109\/10428194.2013.865182","volume":"55","author":"E Clave","year":"2014","unstructured":"Clave E et al (2014) Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis. Leuk Lymphoma 55:1788\u20131795","journal-title":"Leuk Lymphoma"},{"key":"12_CR106","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","volume":"128","author":"T Hayashi","year":"2005","unstructured":"Hayashi T et al (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128:192\u2013203","journal-title":"Br J Haematol"}],"container-title":["Cancer Treatment and Research","Plasma Cell Dyscrasias"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-40320-5_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T06:44:42Z","timestamp":1601102682000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-40320-5_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9783319403182","9783319403205"],"references-count":106,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-40320-5_12","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}